ArticleMolecules (Basel, Switzerland)2020
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Berberine and its structural diversity: structure-activity relationships, molecular mechanisms, and drug discovery opportunities.Molecular biology reports · 2026Review
- Dissimilar effects of stereoisomers and racemic hydroxychloroquine on CaPhysiological reports · 2023Article
- The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy.ACS pharmacology & translational science · 2023Review
- Endocannabinoid Degradation Enzyme Inhibitors as Potential Antipsychotics: A Medicinal Chemistry Perspective.Biomedicines · 2023Review
- Treatment of condylomata acuminata caused by low-risk human papillomavirus with chloroquine phosphate gel.Frontiers in medicine · 2023Article
- Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method.Journal of separation science · 2022Article
- Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept.European journal of pharmacology · 2021Article
- QTc Prolongation in COVID-19 Patients Using Chloroquine.Cardiovascular toxicology · 2021Observational
- 4-Aminoquinoline compounds from the Spanish flu to COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.Pharmaceutics · 2021Review
- Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.Bioscience reports · 2021Article
- Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview.Nutrition (Burbank, Los Angeles County, Calif.) · 2021Review
- Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India.Frontiers in genetics · 2021Review
- Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19).Emergent materials · 2021Review
- The journey of antimalarial drugs against SARS-CoV-2: Review article.Informatics in medicine unlocked · 2021Review
- A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography.Journal of chromatography. A · 2020Article
- Xanthene based hybrid analogues to inhibit protease of novel corona Virus: Molecular docking and ADMET studies.Computational toxicology (Amsterdam, Netherlands) · 2020Article
- Care for Patients with Stroke During the COVID-19 Pandemic: Physical Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2020Review
- Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives.Future medicinal chemistry · 2020Article
- Opportunities for biomaterials to address the challenges of COVID-19.Journal of biomedical materials research. Part A · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The desperate need to find drugs for COVID-19 has indicated repurposing strategies as our quickest way to obtain efficacious medicines. One of the options under investigation is the old antimalarial drug, chloroquine, and its analog, hydroxychloroquine. Developed as synthetic succedanea of cinchona alkaloids, these chiral antimalarials are currently in use as the racemate. Besides the ethical concern related to accelerated large-scale clinical trials of drugs with unproven efficacy, the known potential detrimental cardiac effects of these drugs should also be considered. In principle, the safety profile might be ameliorated by using chloroquine/hydroxychloroquine single enantiomers in place of the racemate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.